Authors
W Schuyler Jones, Hillary Mulder, Lisa M Wruck, Michael J Pencina, Sunil Kripalani, Daniel Muñoz, David L Crenshaw, Mark B Effron, Richard N Re, Kamal Gupta, R David Anderson, Carl J Pepine, Eileen M Handberg, Brittney R Manning, Sandeep K Jain, Saket Girotra, Danielle Riley, Darren A DeWalt, Jeff Whittle, Ythan H Goldberg, Veronique L Roger, Rachel Hess, Catherine P Benziger, Peter Farrehi, Li Zhou, Daniel E Ford, Kevin Haynes, Jeffrey J VanWormer, Kirk U Knowlton, Jennifer L Kraschnewski, Tamar S Polonsky, Dan J Fintel, Faraz S Ahmad, James C McClay, James R Campbell, Douglas S Bell, Gregg C Fonarow, Steven M Bradley, Anuradha Paranjape, Matthew T Roe, Holly R Robertson, Lesley H Curtis, Amber G Sharlow, Lisa G Berdan, Bradley G Hammill, Debra F Harris, Laura G Qualls, Guillaume Marquis-Gravel, Madelaine F Modrow, Gregory M Marcus, Thomas W Carton, Elizabeth Nauman, Lemuel R Waitman, Abel N Kho, Elizabeth A Shenkman, Kathleen M McTigue, Rainu Kaushal, Frederick A Masoudi, Elliott M Antman, Desiree R Davidson, Kevin Edgley, James G Merritt, Linda S Brown, Doris N Zemon, Thomas E McCormick III, Jacqueline D Alikhaani, Kenneth C Gregoire, Russell L Rothman, Robert A Harrington, Adrian F Hernandez
Publication date
2021/5/27
Journal
New England Journal of Medicine
Volume
384
Issue
21
Pages
1981-1990
Publisher
Massachusetts Medical Society
Description
Background
The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.
Methods
Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis. The primary safety outcome was hospitalization for major bleeding, also assessed in a time-to-event analysis.
Results
A total of 15,076 patients were followed for a median of 26.2 months (interquartile range [IQR], 19.0 to 34.9). Before randomization, 13,537 (96.0% of those with available information on previous …
Total citations
Scholar articles
WS Jones, H Mulder, LM Wruck, MJ Pencina… - New England Journal of Medicine, 2021